Active substance |
upadacitinib |
| Holder | AbbVie Belgium sa/nv |
| Status | closed |
| Indication | patients (adults and adolescents ≥ 12 years old) with severe atopic dermatitis who have no other suitable treatment option and are not eligible to participate in a clinical study |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 04/09/2023 |